| Timetable |
| Download Conference Program |
| Download All Abstracts |
| Zoom Access |
| Corporate Program |
Poster Presentations
Day 1, June 22（Sun.）
Room P (Maesato East, Foyer, Ocean Wing)
- 1P-PM-32
Characterizing Microglia in Alzheimer's Disease (AD) and Cerebral Amyloid Angiopathy (CAA) with MALDI HiPLEX-IHC
(1Doshisha Univ., 2Bruker Japan, 3JASRI/SPring-8, 4BBAR)
oNaoki Tsujimura1, Rikuya Yoshimura1, Takashi Nirasawa2, Yumiko Toyama1, Maiko Okamura1, Masato Hoshino3, Shuji Yamashita1, Yuko Saito4, Shigeo Murayama4, Kazuhiro Irie1, Masaya Ikegawa1
Neuropathology of Alzheimer's disease (AD) is characterized by the accumulation and aggregation of Amyloid β (Aβ) peptides into extracellular plaques of the brain. Aβ is deposited not only in cerebral parenchyma but also in leptomeningeal and cerebral vessel walls, known as cerebral amyloid angiopathy (CAA). Neuroinflammation might play a role in the steps between vascular Aβ accumulation and vascular injury resulting in vessel rupture and haemorrhage. We have succeeded in obtaining comprehensive Aβ mapping with our standard proptocol of Matrix-assisted laser desorption/ionization-based imaging mass spectrometry (MALDI-IMS) and a newly developing MALDI HiPLEX-IHC. As the precise role of neuroinflammation or a causal factor in vascular damage remains less clear, we will try to characterize microglia in AD and CAA, integrating two-dimensional (2D) MALDI-MSI data into three-dimensional (3D) data obtained by synchrotron radiation-based X-ray phase-contrast microtomography. Current strategy accelerates the diagnosis and the clarification of the pathogenesis of CAA and AD as well as MRI signal abnormalities called amyloid-related imaging abnormalities (ARIA) as possible spontaneous or treatment-related adverse events when using monoclonal antibodies that target amyloid-β. In conclusion, MALDI-IMS and MALDI HiPLEX-IHC integrating with X-ray Phase-contrast microtomography is powerful approach in elucidating pathology of AD and CAA brains.